| Abstract |
[Abstract] Objective: To observe the effects of buspirone and paroxetine on anxiety patients and Hamilton Anxiety Scale (HAMA). Methods: 90 patients with anxiety disorder admitted from January 2019 to June 2021 were randomly divided into observation group (45 cases were included and treated with buspirone + paroxetine), control group (45 cases were included and treated with buspirone only), HAMA score, self rating Anxiety Scale (SAS), Pittsburgh sleep quality index (PSQI), adverse reaction symptom scale (TESS) and Clinical efficiency. Results: (1) there was no significant difference in HAMA, SAS and PSQI scores between the groups before treatment, P > 0.05; The scores of HAMA, SAS and PSQI in the observation group were lower at 1, 2, 4 and 8 weeks of treatment (P < 0.05); (2) The Tess scores of the observation group at 1 week (3.79 ± 1.05), 2 weeks (3.37 ± 0.90), 4 weeks (2.59 ± 0.57) and 8 weeks (2.28 ± 0.64) were not significantly different from those of the control group (3.55 ± 1.02), (3.42 ± 0.96), (2.42 ± 0.68) and 2.36 ± 0.71), P > 0.05. The degree of adverse reactions was mild and tolerable; (3) In terms of clinical effective rate, the observation group (95.56%) was better than the control group (80.00%), P < 0.05. Conclusion: buspirone + paroxetine treatment for anxiety patients can enhance the curative effect, reduce anxiety and sleep disorders as soon as possible. In addition, the risk of adverse reactions is low, which is worthy of promotion.
|